– Final stage of Oxford Vacmedix OVM-200 licensing in the UK
– DxVx plans to continue its own clinical trials in Asiaincluding Korea and China
Seoul, South Korea, November 24, 2023 /PRNewswire/ — DxVx announced today that it will conduct its own clinical trials of OVM-200, an anti-cancer vaccine from Oxford Vacmedix (OVM) under a licensing agreement and will continue its development through to its own knowledge in the development of new drugs. Currently, the vaccine has completed a phase 1a clinical trial in the first half of this year and is expected to enter a phase 1b trial soon.
OVM-200 has achieved positive results in a Phase 1a clinical trial and a new publication in Advanced Therapeutics comprehensively examines the rationale and preclinical results of OVM-200 alone and in combination. A phase 1b clinical trials are being discussed and are expected to be conducted in the UK by OVM and in Asiaincluding Korea and Chinaby Dx&Vx.
OVM-200 is a therapeutic vaccine that enters the body and kills cancer cells. Over time, even if new cancer cells appear, immune cells remember and eliminate the cancer cells.
In particular, the ROP (Recombinant Overlapping Peptide) technology used in OVM-200 cancer vaccines significantly improves immunity and vaccine effectiveness. In addition, targeting survivin (anti-apoptotic protein), which is closely linked to cancers, and the fact that DxVx has a large number of experts with rich experience in the development and commercialization of new drugs are also considered. as differentiators.
OVM-200 is highly safe because it is a peptide vaccine. Vaccines based on mRNA or viral particles are not immune to the safety concerns highlighted by the COVID-19 pandemic. In contrast, vaccines based on recombinant proteins have significant advantages in terms of stability, as their safety has been proven over a long period of time.
Additionally, the method of selecting and targeting a single antigenic peptide only works for a limited number of HLA (human leukocyte antigen), an identifier that helps the immune system distinguish itself from foreign substances, but in the case of peptide complexes, it is expected to increase the effectiveness of the treatment because it is likely to act on more diverse HLAs (around 30 types).
Additionally, OVM’s Recombinant Stacked Peptide (ROP) platform technology has superior production and cost advantages over existing peptide complex technology, which produces and mixes multiple peptides. The ROP platform technology is a peptide complex technology that produces a long overlapping peptide, which is cleaved into individual peptides by human enzymes in vivo. So it is expected to have advantages in terms of CMC, production process, cost, etc.
DX&VX believes that if adequate data is collected demonstrating that OVM-200 improves the prognosis of patients undergoing chemotherapy and prevents relapses, it will also be possible to develop a vaccine for cancer prevention.
Safety is paramount when it comes to preventative vaccines. Even mild toxicity is unacceptable in terms of safety, as it is a preventative vaccine to be given to healthy people who have not yet been diagnosed. OVM-200 is a traditional recombinant protein vaccine and has a very high chance of success because it is a type of vaccine that has a long history of clinical safety.
A DxVx official said it plans to complete the licensing process soon and move on to the phase 1b and phase 2 clinical trials in major Asian countries (Korea, China and considering India in the future). They will attempt to launch it via an accelerated approval that will allow patients to benefit early from effective drugs before all clinical trials are completed around 2027. Of course, they are also considering collaborations with major global pharmaceutical companies if necessary for the future.
Dx&Vx is currently agreeing licensing terms with OVM and coordinating final details.
Meanwhile, OVM is a spin-off company of Oxford University in the United Kingdom, and Dx&Vx is the largest shareholder with a 43% stake.
Show original content:https://www.prnewswire.com/apac/news-releases/dxvx-plans-to-make-a-license-in-agreement-of-ovm-200-and-conduct-clinical-trials-in-asia- 301997047.html
SOURCE Dx&Vx
